On 13 December 2012, the Company announced the sale of its Prevascar assets to the Palo Alto based, Delaware incorporated pharmaceutical company Targenics Inc.
The disposal of Prevascar has led to a fundamental change in the Company’s business as it no longer engages in any trading activities. The Company now constitutes an investing company, as provided for by Rule 15 of the AIM Rules for Companies issued by the London Stock Exchange. Accordingly, it was necessary for the Company to adopt and implement an investing policy. On 24 January 2013, the shareholders in General Meeting approved the policy - details of which are available here.
An indexed pdf version of our 2012 Annual Report is now available in our Investors' section. Interim announcements can be found in the News section at the bottom of this page.